Invention Grant
- Patent Title: Substituted inhibitors of menin-MLL and methods of use
-
Application No.: US16082649Application Date: 2017-03-15
-
Publication No.: US10781218B2Publication Date: 2020-09-22
- Inventor: Tao Wu , Liansheng Li , Yi Wang , Pingda Ren , Jolanta Grembecka , Tomasz Cierpicki , Szymon Klossowski , Jonathan Pollock , Dmitry Borkin
- Applicant: Kura Oncology, Inc. , The Regents of The University of Michigan
- Applicant Address: US CA San Diego US MI Ann Arbor
- Assignee: KURA ONCOLOGY, INC.,THE REGENTS OF THE UNIVERSITY OF MICHIGAN
- Current Assignee: KURA ONCOLOGY, INC.,THE REGENTS OF THE UNIVERSITY OF MICHIGAN
- Current Assignee Address: US CA San Diego US MI Ann Arbor
- Agency: Wilson Sonsini Goodrich & Rosati
- International Application: PCT/US2017/022564 WO 20170315
- International Announcement: WO2017/161028 WO 20170921
- Main IPC: A61K31/519
- IPC: A61K31/519 ; C07D495/04 ; A61P35/00
Abstract:
The present disclosure provides compounds of Formula (II-A), which inhibit the interaction of menin with one or more of MLL1, MLL2 and MLL-fusion oncoproteins. Also disclosed are methods for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
Public/Granted literature
- US20190092784A1 SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE Public/Granted day:2019-03-28
Information query
IPC分类:
